Focus On: Charlotte’s Web is ready to lead the CBD marketplace
Talk to officials at Charlotte’s Web, and it is pretty easy to get the feeling that this is a company that is ready to break loose on the domestic mass retail marketplace.
With sales nearing $100 million annually and a position at the top of the heap in the emerging, yet still undefined, CBD/hemp category, Charlotte’s Web executives said that the sky is the limit for the company. They are especially confident since they have barely touched the mass retail industry, with about two-thirds of the Boulder, Colo.-based company’s sales coming through online activity.
Yet, becoming a player in the CBD world is not that easy these days. Competition for retail space is stiff, quality issues are growing and many merchants are still a bit gun shy when it comes to stocking the category.
Let’s be clear, Elsner has a big hill to climb. CBD has been the talk of the mass retail industry for much of the last three years. Backed by strong consumer demand, explosive media coverage and a ton of money from private equity and other resources, the category was poised to have a breakout year in 2019. But, the Food and Drug Administration spoiled the fun by stating late last year that it is illegal to market CBD by adding it to a food or labeling it as a dietary supplement. The agency also stated that CBD is not “generally recognized as safe” for use in human or animal food.
Mass retailers hit the pause button with the entire category, with many worried that moving forward too quickly without government approval would put them at risk. Plus, as with many new and trendy categories, everyone wants a piece of the action.
To that end, the company started CW Labs, an internal division for research and development, substantially expanding on the company’s efforts around the science of hemp-derived phytocannabinoids, terpenes and flavonoid compounds. Under the leadership of recently hired Tim Orr, senior vice president of innovation, CW Labs is working with the University of Buffalo — part of the State University of New York system — to provide a boost to the company’s product portfolio with science-based innovation, including studies on safety and effectiveness, while advancing clinical trials. CW Labs is currently engaged in double-blinded, placebo-controlled human clinical trials, addressing hemp-based solutions for several need states.